Track topics on Twitter Track topics that are important to you
Surge Discovery(TM) fully replaces older hybridoma and phage display technologies
South San Francisco, CA (PRWEB) June 20, 2017
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch of its new Surge(TM) Discovery service at the BIO 2017 International Conference in San Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present on Surge at the conference.
Surge is the new, fully integrated therapeutic antibody discovery and engineering service from GigaGen that delivers fully characterized monoclonal antibodies to a pharmaceutical customer within six weeks, entirely replacing hybridoma and phage display. Surge’s ultra-high throughput process generates a display library for each immunized mouse, screens for high affinity binders, and validates functionality. With Surge, pharmaceutical companies can now generate more target-binding antibodies with deeper repertoire diversity than previously possible with traditional technologies, so that they can find the best clinical candidates early in the discovery process.
Surge is the only discovery method that:
Dr. Johnson’s presentation will take place on Wednesday, June 21st, 2017, at 10:45am in Room 11B – Upper Level at the San Diego Convention Center. GigaGen has published a technical white paper describing the technology and highlighting in detail a customer’s discovery success story using Surge. Copies of the white paper will be available after the presentation and at GigaGen’s kiosk in the NIH Innovation Zone.
GigaGen is a biopharmaceutical company developing novel antibody therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of entire immune repertoires, capturing and genetically analyzing B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. For more information visit GigaGen.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14438255.htmNEXT ARTICLE
Hybridoma technology is a technology of forming hybrid cell lines (called hybridomas) by fusing an antibody-producing B cell with a myeloma (B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of antibody cha...
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...